drugset / Trial / NCT00219089

A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.

NCT00219089

Phase 3 Completed 839 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

To demonstrate the efficacy and safety of aliskiren given to patients with both hypertension and diabetes mellitus

Timeline

Start
2004-11
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg

Indications

No indication recorded.